Cure Hepatitis C Act of 2026
Sponsored By: Representative Miller-Meeks, Mariannette [R-IA-1]
Introduced
Summary
This bill would create a federal program to eliminate hepatitis C by expanding testing, treatment, and coordination nationwide. It sets a national strategy, a public dashboard, and a subscription procurement model for treatments to boost access and monitoring.
Show full summary
- People at risk and affected communities: Increases funding for screening, diagnosis, treatment, care coordination, and outreach aimed at priority populations and people with high incidence of hepatitis C.
- People in correctional settings and those reentering the community: Authorizes distribution of treatments and testing to State and local correctional systems and the Bureau of Prisons and funds continuity-of-care measures after release.
- Health providers, tribal programs, and health centers: Creates a subscription‑based purchase model, supports point-of-care diagnostic tests, funds provider training, and channels grants to community health centers, Indian health programs, opioid treatment programs, and behavioral health clinics.
*Would appropriate $5.5 billion for fiscal year 2027 with funds available through 2033 and authorize up to $20 million for diagnostics, increasing federal spending.*
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
No Medicare cost-sharing for Hep C drugs
For plan years 2028 through 2032, this bill would eliminate the Medicare Part D deductible and all coinsurance or cost-sharing for direct-acting antiviral hepatitis C drugs. The Secretary could delay start from 2028 to 2029. The change would also remove deductible and cost-sharing for low-income subsidy beneficiaries for the same years.
Major funding for Hepatitis C program
This bill would appropriate $5.5 billion for FY2027, available through FY2033, to buy and distribute hepatitis C treatments under a subscription model. It would also appropriate $4.283 billion for FY2027, available through FY2033, for program awards and contracts. The Secretary would transfer $25 million of the funds to the Federal Bureau of Prisons for BOP hepatitis C work. HHS could not use more than 5% of the main funds for administrative costs, and the funds would be subject to rules in Public Law 118-47.
Subscription prices counted for Medicaid
This bill would require that prices charged under the federal subscription program for hepatitis C drugs be counted when Medicaid calculates Best Price and Average Manufacturer Price. If enacted, that would lower Medicaid's net drug costs but could change how drug makers set prices and rebates across the market.
More hepatitis C testing and care
This bill would fund training, technical assistance, and awards so more places can test for and treat hepatitis C. Grants and contracts would go to community health centers, States and local areas, correctional systems, Tribal health programs, opioid treatment programs, and behavioral health clinics. HHS could buy and distribute point-of-care hepatitis C tests and use up to $20 million for test development. A pilot would fund up to 25 Title XXVI sites to provide treatment services.
National Hepatitis C program and plan
This bill would require HHS to start a Hepatitis C Elimination Program within 90 days. The Secretary would publish a national strategy and implementation plan within 180 days. The bill would create an advisory committee and an interagency working group to guide the program. HHS would also make a public dashboard and run a national awareness campaign tailored to priority groups.
Sponsors & CoSponsors
Sponsor
Miller-Meeks, Mariannette [R-IA-1]
IA • R
Cosponsors
Rep. DeGette, Diana [D-CO-1]
CO • D
Sponsored 7/14/2026
Rep. Johnson, Henry C. "Hank" [D-GA-4]
GA • D
Sponsored 7/14/2026
Rep. Bacon, Don [R-NE-2]
NE • R
Sponsored 7/14/2026
Rep. Gottheimer, Josh [D-NJ-5]
NJ • D
Sponsored 8/10/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov